The treatment of leukemia mice with Tie2-monocytes, engineered for the release of IFNγ and TNFα, induced the activation of the CD8 + effector T cells, but also of MHC II + memory T cells and significantly delayed tumor progression. Here, TEK is linked to neoplasm.